Focused on rare disease and specialty medicines, the company develops and markets therapies for autoimmune, inflammatory, and ophthalmic conditions. Its portfolio has included drugs such as Tepezza for thyroid eye disease and Krystexxa for chronic gout, which have driven revenue growth through niche...
No congressional trades have been disclosed for Horizon Pharma (HOPH) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.